FLOW CHEMISTRY
The objective is not simply to run chemistry in flow at small scale, but to establish a process pathway that can be carried forward through the pilot phase and into production. The distinction matters because good laboratory data alone is not enough.
For flow chemistry to be useful industrially, the process must also support consistent operation and translate into something a manufacturing team can run and maintain over time. Corning AFRs have found a place here as a practical tool for developing and transferring suitable chemistries.
Small internal volumes and high surface-area-to-volume ratios allow close control of heat transfer, while engineered channels improve mixing and mass transfer. Those features can make a meaningful difference for chemistries that are limited in batch by thermal gradients, mixing inefficiencies and reactive or unstable intermediates.
Practical move to flow
The industrial value of this approach can be demonstrated through a real manufacturing example. Angelini Pharma’ s work on trazodone hydrochloride( HCl, Figure 1), an antidepressant it discovered and now distributes globally as a generic drug, is one such case. The main production site is at Aprilia, Italy( pictured). Rather than starting with a process designed from the outset for continuous processing, the project revisited an established batch process and assessed whether it could be reorganised in flow to reduce complexity without compromising requirements.
Trazodone HCl was a useful candidate for that exercise. Angelini’ s production volume was around 230 tonnes / year, and the batch process already had a well-established quality profile and regulatory history. The issue was not poor chemistry but process complexity.
Angelini’ s review of the batch process identified 21 separate operations, including multiple isolation, handling and treatment steps, which added complexity to execution and transfer. One of the main constraints centred on the intermediate N-( 3-chlorophenyl)-N’-( 3-chloropropyl)-piperazine. This was not stable as a free base, so it had to be isolated as a salt and stored before the next stage. It is also genotoxic, making its handling especially sensitive from both operatorexposure and process standpoints.
By redesigning the sequence in flow, Angelini was able to use the intermediate as a free base without isolating the salt. That substantially simplified the process and made it possible to eliminate or reduce several intermediate operations, including salification, salt isolation, drying, loading for use, acid-base treatment and related work-up steps.
Development to implementation
The process was not transferred in a single leap. Angelini first analysed the batch process and adapted it to flow conditions, studying variables such as temperature, residence time, reagent concentration, base selection and system configuration in order to identify conditions that delivered the right balance of yield, purity and productivity.
Once those conditions had been defined, the process was transferred progressively from laboratory scale with the Corning AFR Low-Flow reactor to pilot scale with the AFR G1 and then to industrial scale with AFR G4( pictured).
That gradual progression is worth stressing, because it reflects how industrial flow projects usually develop. Continuous processing is rarely adopted as a full replacement for batch in one step. More often, it is introduced where it makes the most technical sense, then expanded as understanding and confidence improve.
In Angelini’ s case, the project moved over time from a fully batch process to a more integrated model in which reaction and work-up were progressively reconfigured. The process changed, but so did the organisation’ s familiarity with continuous flow manufacturing.
That made the project important beyond the chemistry itself. The
Aprilia is the main production site for trazodone API
SEP / OCT 2026 SPECCHEMONLINE. COM
37